SAN FRANCISCO, March 20 /PRNewswire-FirstCall/ -- Medivation, Inc. (NASDAQ:MDVN) today announced that its common stock will begin trading on The...
SAN FRANCISCO, March 19 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that six-month results from its randomized...
Dutton Associates continues its coverage of Medivation Inc. (AMEX:MDV) reiterating a Strong Speculative Buy rating and a $27.00...
SAN FRANCISCO, March 8 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that The Nasdaq Listing Qualifications Department...
SAN FRANCISCO, March 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that David Hung, M.D., president and chief...
- Data Presented in Oral and Poster Presentations at ASCO's Prostate Cancer Symposium - SAN FRANCISCO, Feb. 26 /PRNewswire-FirstCall/...
SAN FRANCISCO, Feb. 16 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that preclinical efficacy data on MDV3100, a novel...
SAN FRANCISCO, Feb. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that David Hung, M.D., president and chief executive...
SAN FRANCISCO, Jan. 30 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that results of its Phase 2 efficacy study of...
SAN FRANCISCO, Jan. 17 /PRNewswire/ -- Medivation, Inc. (AMEX:MDV) today announced that it has appointed Lisa Taylor as vice president of...
Dutton Associates continues its coverage of Medivation Inc. (AMEX:MDV) reiterating a Strong Speculative Buy rating and a $22.00...
SAN FRANCISCO, Dec. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced the appointment of Sue Wollowitz, Ph.D., as vice...
SAN FRANCISCO, Dec. 4 /PRNewswire/ -- Medivation, Inc. (AMEX:MDV) announced today that its Board of Directors has adopted a Shareholder Rights...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads